Myriad Genetics (MYGN) stock plummeted over 10% in pre-market trading on Tuesday, following the company's fourth-quarter 2024 earnings report and conference call. The decline was primarily driven by weaker-than-expected first-quarter 2025 guidance and concerns over the impact of UnitedHealthcare's decision not to cover the company's GeneSight pharmacogenomic test.
For the fourth quarter, Myriad Genetics reported adjusted earnings per share of $0.03, in line with analysts' expectations. Revenue of $210.6 million also narrowly missed the consensus estimate of $211.6 million. However, the company's guidance for the first quarter of 2025 significantly missed expectations, with an anticipated adjusted loss per share of $(0.04)-(0.08) compared to the consensus estimate of $(0.03).
Despite the weak first-quarter guidance, Myriad Genetics maintained its full-year 2025 adjusted EPS guidance of $0.07-$0.11, in line with analysts' expectations. The company cited an expected acceleration in hereditary cancer testing volumes in the second half of 2025 as a key driver for the full-year outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.